Abstract
Cardio vascular disease (CVD) is the end result of the accumulation of atheromatous plaques within the walls of the coronary arteries and remains the leading cause of death worldwide. Vascular inflammation and associated ongoing inflammatory responses have been considered as the critical culprits in the pathogenesis of CVD. Moreover, the activation of inflammatory pathways is not confined to coronary lesions only but involves the activation of neutrophils, monocytes and lymphocytes in peripheral blood. In view of high mortality rate associated with this devastated disease, it is essential that CVD and related complications should be taken care off at its earliest. To achieve that goal, some inflammatory mediators could be potentially targeted. In the current article, we will highlight targeting some inflammatory mediators viz. IL-1, IL-6, TNF-α etc for CVD management. As far as our knowledge goes, we are for the first time reporting the targeting inflammatory mediators especially IL-1, IL-6 and TNF-α together in a single article. Based on our review, we believe that scientific community will come up with certain anti-inflammatory agents against atherosclerosis in near future and hopefully that will be used for the successful management of CVD patients.
Keywords: Cardiovascular disease, Inflammation, IL-1, IL-6, TNF-α.
Current Pharmaceutical Design
Title:Cardiovascular disease management through restrained inflammatory responses
Volume: 22 Issue: 7
Author(s): Nasimudeen R. Jabir and Shams Tabrez
Affiliation:
Keywords: Cardiovascular disease, Inflammation, IL-1, IL-6, TNF-α.
Abstract: Cardio vascular disease (CVD) is the end result of the accumulation of atheromatous plaques within the walls of the coronary arteries and remains the leading cause of death worldwide. Vascular inflammation and associated ongoing inflammatory responses have been considered as the critical culprits in the pathogenesis of CVD. Moreover, the activation of inflammatory pathways is not confined to coronary lesions only but involves the activation of neutrophils, monocytes and lymphocytes in peripheral blood. In view of high mortality rate associated with this devastated disease, it is essential that CVD and related complications should be taken care off at its earliest. To achieve that goal, some inflammatory mediators could be potentially targeted. In the current article, we will highlight targeting some inflammatory mediators viz. IL-1, IL-6, TNF-α etc for CVD management. As far as our knowledge goes, we are for the first time reporting the targeting inflammatory mediators especially IL-1, IL-6 and TNF-α together in a single article. Based on our review, we believe that scientific community will come up with certain anti-inflammatory agents against atherosclerosis in near future and hopefully that will be used for the successful management of CVD patients.
Export Options
About this article
Cite this article as:
Jabir R. Nasimudeen and Tabrez Shams, Cardiovascular disease management through restrained inflammatory responses, Current Pharmaceutical Design 2016; 22 (7) . https://dx.doi.org/10.2174/1381612822666151209153823
DOI https://dx.doi.org/10.2174/1381612822666151209153823 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia
Medicinal Chemistry Anti-Platelet Therapy and Aspirin Resistance – Clinically and Chemically Relevant?
Current Medicinal Chemistry Empowering Translational Research in Fetal Growth Restriction: Sheep and Swine Animal Models
Current Pharmaceutical Biotechnology Renal Cytochrome P450-Derived Eicosanoids and Hypertension
Current Hypertension Reviews An Overview of Non-Neural Sources of Calcitonin Gene-Related Peptide
Current Medicinal Chemistry Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Alport Syndrome: A Comprehensive Review on Genetics, Pathophysiology, Histology, Clinical and Therapeutic Perspectives
Current Medicinal Chemistry Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and Pharmacodynamics
Drug Metabolism Letters Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design The Control of Arterial Hypertension: Epidemiological and Economic Challenge
Current Hypertension Reviews Update on the Pharmacological Treatment of Alzheimers Disease
Current Neuropharmacology Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Cleavage of Human Apolipoprotein(a) Coated on the Surface of Consituents of the Vascular Extracellular Matrix by Pancreatic Elastase and Metalloproteinase-12. Different Partitions Between Cleaved NTerminal and C-Terminal Domains
Vascular Disease Prevention (Discontinued) Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets Advances in Sickle Cell Disease Treatment: from Drug Discovery Until the Patient Monitoring
Cardiovascular & Hematological Agents in Medicinal Chemistry Effects of Lipid-Lowering Drugs on Adiponectin
Current Vascular Pharmacology Weka Machine Learning for Predicting the Phospholipidosis Inducing Potential
Current Topics in Medicinal Chemistry Arterial Hypertension and Kidney Circulation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)